Aducanumab for the treatment of Alzheimer's disease: a systematic review

Abstract

Aducanumab is a novel disease‐modifying anti‐amyloid‐beta (Aβ) human monoclonal antibody specifically targeted to the pathophysiology of Alzheimer's disease (AD). It was granted for treating AD in June 2021 by the United States Food and Drug Administration. We systematically analyzed available trials to evaluate the efficacy and safety of aducanumab treating AD. We followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta‐Analysis) guidelines. We conducted an extensive literature search using the electronic databases MEDLINE through PubMed, EMBASE, Cochrane, Web of Science, and Scopus for suitable studies on aducanumab. We considered human clinical trials of aducanumab, assessing its efficacy and adverse effects in treating AD, excluding any experimental animal studies. We included three randomised controlled trials. Studies reported that aducanumab reduced brain amyloid‐beta plaques in a time‐ and dose‐dependent manner (dose–response, P < 0.05) and a slowed decline in cognition (22% reduction) in the high‐dose treated group, difference of −0.39 versus placebo in Clinical Dementia Rating Scale Sum Boxes (95% CI, −0.69 to −0.09; P = 0.012) along with a reduced amyloid positron emission tomography standard uptake value ratio score (P < 0.001) and plasma p181‐tau (phosphorylated tau) level. Amyloid‐related imaging abnormality was reported as a serious adverse event and was profound in high‐dose treated group (425/1029 in 10 mg/kg). Aducanumab has been reported to affect two main pathophysiologic hallmarks (Aβ and tau) of AD. We suggest future studies addressing aducanumab's efficacy and safety to confirm that the benefit of this drug outweighs the risk.